Skip to main content
SpringerLink
Log in

Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results

  • Short Communication
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The initial treatment of high-grade glioma often consists of surgery and radiation therapy. Chemotherapy is used in cases of recurrence or after incomplete surgery. Because of the many potential serious side-effects of chemotherapy, early tumour response evaluation is necessary to enable clinicians to adapt the treatment. However, response monitoring with computed tomography (CT) or magnetic resonance imaging (MRI) is often difficult. The aim of this study was to assess the value of repeated technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) single-photon emission computerised tomography (SPECT) for this purpose. Fifteen patients with malignant glioma were investigated with MIBI SPECT. Imaging was performed 1 h after the intravenous injection of 555 MBq of 99mTc-MIBI, using a dedicated SPECT system (Tomomatic 564, Medimatic, Denmark). Overall, 57 investigations were performed. A MIBI uptake index was computed as the ratio of counts in the lesion to those in the contralateral region. Previous study had shown a cut-off value of 2.0 to be appropriate. SPECT indices were compared with neurological evaluation, CT or MRI. This assessment was performed every 4 months during and after the treatment. Six patients showed an increased MIBI index associated with clinical or radiological progression of disease during chemotherapy. After an initial response to therapy, three patients showed an increased MIBI index despite chemotherapy, demonstrating secondary resistance to therapy. Six patients showed a decreased MIBI index, demonstrating a good response to therapy. The first nine patients died shortly after the last SPECT scan (average duration of survival, 4 months). The therapeutic protocol was modified in six cases, but successfully so in only two. In some cases, tumour progression was diagnosed earlier with SPECT than on the basis of clinical or MRI signs. Early response or resistance to chemotherapy is detectable by99mTc-MIBI SPECT. Therefore this functional imaging modality could be considered as a valuable tool to permit effective adaptation of the therapeutic regimen in patients treated for recurrent high-grade glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3A–C

References

  1. Stewart LA. Chemotherapy in adult high grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002; 359:1011–1018.

    Article  PubMed  Google Scholar 

  2. Källen K, Geijer B, Malmström P, et al, Quantitative201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 2000; 21:259–267.

    Article  PubMed  Google Scholar 

  3. Roesdi MF, Postma TJ, Hoekstra OS, et al. Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 1998; 40:251–255.

    Google Scholar 

  4. Koyuncu A, Kracht LW, Herholz K, et al. Monitoring the effect of chemotherapy in gliomas. Neuro-oncology 2000; 2:S40.

    Google Scholar 

  5. Brock CS, Young H, O’Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000; 82:608–615.

    Article  CAS  PubMed  Google Scholar 

  6. Lamy-Lhuillier C, Dubois F, Blond S, et al. Intérêt de la tomoscintigraphie cérébrale au sestamibi marqué au technétium dans le diagnostic différentiel récidive tumorale–radionécrose des tumeurs gliales sus-tentorielles de l’adulte. Neurochirurgie 1999; 45:10–117.

    Google Scholar 

  7. Fuster D, Munoz M, Pavia J, Palacin A, Bellet N, Mateos JJ, Martin F, Ortega M,Setoain FJ, Pons F. Quantified99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99mTc-MIBI uptake. Nucl Med Commun 2002; 23:31–38.

    Article  CAS  PubMed  Google Scholar 

  8. Yokogami K, Kawano H, Moriyama T, Uehara H, Sameshima T, Oku T, Goya T, Wakisaka S, Nagamachi S, Jinnouchi S, Tamura S. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? Eur J Nucl Med 1998; 25:401–409.

    Article  CAS  PubMed  Google Scholar 

  9. Beauchesne P, Soler C. Correlation of99mTc-MIBI brain SPECT (functional index ratios) and survival after treatment failure in malignant glioma patients. Anticancer Res 2002; 22:3081–3085.

    CAS  PubMed  Google Scholar 

  10. Soler C, Beauchesne P, Maatougui K, et al. Technetium-99m sestamibi brain single photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998; 25:1649–1657.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Florence Prigent-Le Jeune

    Present address: Service de Médecine Nucléaire, Centre Eugène Marquis, Boulevard de la Bataille Flandres-Dunkerque, BP 6279, 35062, Rennes cedex, France

Authors and Affiliations

  1. Service de Médecine Nucléaire, Unité d’imagerie fonctionnelle cérébrale, Hôpital Roger Salengro, CHRU de Lille, Lille, France

    Florence Prigent-Le Jeune, Sarah Perez & Marc Steinling

  2. Service de Neurochirurgie, Hôpital Roger Salengro, CHRU de Lille, Lille, France

    François Dubois & Serge Blond

Authors
  1. Florence Prigent-Le Jeune
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. François Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Serge Blond
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marc Steinling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florence Prigent-Le Jeune.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prigent-Le Jeune, F., Dubois, F., Perez, S. et al. Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results. Eur J Nucl Med Mol Imaging 31, 714–719 (2004). https://doi.org/10.1007/s00259-004-1463-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1463-7

Keywords

Search

Navigation